0001192482-19-000388.txt : 20191107
0001192482-19-000388.hdr.sgml : 20191107
20191107210509
ACCESSION NUMBER: 0001192482-19-000388
CONFORMED SUBMISSION TYPE: 3
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20191107
FILED AS OF DATE: 20191107
DATE AS OF CHANGE: 20191107
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Quaker BioVentures II LP
CENTRAL INDEX KEY: 0001497725
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 3
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39130
FILM NUMBER: 191201890
BUSINESS ADDRESS:
STREET 1: QUAKER BIOVENTURES
STREET 2: 2929 ARCH STREET
CITY: PHILADELPHIA
STATE: PA
ZIP: 19104
BUSINESS PHONE: (215) 988-6800
MAIL ADDRESS:
STREET 1: QUAKER BIOVENTURES
STREET 2: 2929 ARCH STREET
CITY: PHILADELPHIA
STATE: PA
ZIP: 19104
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Quaker BioVentures Capital II, L.P.
CENTRAL INDEX KEY: 0001583083
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 3
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39130
FILM NUMBER: 191201891
BUSINESS ADDRESS:
STREET 1: CIRA CENTER
STREET 2: 2929 ARCH STREET
CITY: PHILADELPHIA
STATE: PA
ZIP: 19104
BUSINESS PHONE: 215-988-6800
MAIL ADDRESS:
STREET 1: CIRA CENTER
STREET 2: 2929 ARCH STREET
CITY: PHILADELPHIA
STATE: PA
ZIP: 19104
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: TELA Bio, Inc.
CENTRAL INDEX KEY: 0001561921
STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
IRS NUMBER: 455320061
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1 GREAT VALLEY PARKWAY, SUITE 24
CITY: MALVERN
STATE: PA
ZIP: 19355
BUSINESS PHONE: 484-320-2930
MAIL ADDRESS:
STREET 1: 1 GREAT VALLEY PARKWAY, SUITE 24
CITY: MALVERN
STATE: PA
ZIP: 19355
3
1
edgar.xml
PRIMARY DOCUMENT
X0206
3
2019-11-07
0
0001561921
TELA Bio, Inc.
TELA
0001497725
Quaker BioVentures II LP
150 MONUMENT ROAD, SUITE 207
BALA CYNWYD
PA
19004
0
0
1
0
0001583083
Quaker BioVentures Capital II, L.P.
150 MONUMENT ROAD, SUITE 207
BALA CYNWYD
PA
19004
0
0
1
0
Common Stock
29288
D
Series A Preferred Stock
Common Stock
345489
D
Series B Preferred Stock
Common Stock
516947
D
Warrant
1.16
2017-01-18
2027-01-18
Series B Preferred Stock
446813
D
These securities are owned of record by Quaker BioVentures II, L.P. ("Quaker"). Quaker BioVentures Capital II, L.P. ("Quaker Capital") is the general partner of Quaker, has voting and dispositive power over the securities held by Quaker, and thus may be deeemd to beneficially own these securities. Voting and investment determinations made by Quaker Capital with respect to the securities held by Quaker are made by an investment committee of Quaker Partners. Quaker Capital disclaims beneficial ownership of these securities except to the extent of its pecuniary interest therein.
Shares of Series A and Series B Preferred Stock (collectively, the "Preferred Stock") have no expiration date and are convertible, at the option of the holder, into shares of Common Stock at the then-effective conversion rate for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Issuer's Third Amended and Restated Certificate of Incorporation (as amended, the "Certificate of Incorporation")). The shares of Preferred Stock will automatically convert into shares of Common Stock at the then-effective conversion rate for no additional consideration (subject to the payment in cash in lieu of any fractional shares in accordance with the Certificate of Incorporation) immediately prior to the closing of the Issuer's initial public offering.
Shares of Series A Preferred Stock are convertible into shares of Common Stock at a 1-for-1 conversion rate.
Shares of Series B Preferred Stock are convertible into shares of Common Stock at a 1-for-1 conversion rate.
Quaker BioVentures II, L.P. By: Quaker Bioventures Capital II, L.P., its general partner By Quaker BioVentures Capital II, LLC, its general partner By: /s/ Adele C. Oliva, Executive Manager
2019-11-07
Quaker Bioventures Capital II, L.P., its general partner By: Quaker BioVentures Capital II, LLC, its general partner By: /s/ Adele C. Oliva, Executive Manager
2019-11-07